AU2012335277B2 - Compositions and methods for treatment of cytomegalovirus - Google Patents

Compositions and methods for treatment of cytomegalovirus Download PDF

Info

Publication number
AU2012335277B2
AU2012335277B2 AU2012335277A AU2012335277A AU2012335277B2 AU 2012335277 B2 AU2012335277 B2 AU 2012335277B2 AU 2012335277 A AU2012335277 A AU 2012335277A AU 2012335277 A AU2012335277 A AU 2012335277A AU 2012335277 B2 AU2012335277 B2 AU 2012335277B2
Authority
AU
Australia
Prior art keywords
leu
ser
thr
val
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012335277A
Other languages
English (en)
Other versions
AU2012335277A1 (en
Inventor
David E. Anderson
Anne-Catherine Fluckiger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Variation Biotechnologies Inc
Original Assignee
Variation Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc
Publication of AU2012335277A1 publication Critical patent/AU2012335277A1/en
Priority to AU2018203538A priority Critical patent/AU2018203538A1/en
Application granted granted Critical
Publication of AU2012335277B2 publication Critical patent/AU2012335277B2/en
Priority to AU2020264275A priority patent/AU2020264275B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20245—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
AU2012335277A 2011-11-11 2012-11-09 Compositions and methods for treatment of cytomegalovirus Active AU2012335277B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018203538A AU2018203538A1 (en) 2011-11-11 2018-05-18 Compositions and methods for treatment of cytomegalovirus
AU2020264275A AU2020264275B2 (en) 2011-11-11 2020-11-03 Compositions and methods for treatment of cytomegalovirus

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161558800P 2011-11-11 2011-11-11
US61/558,800 2011-11-11
US201261654157P 2012-06-01 2012-06-01
US61/654,157 2012-06-01
PCT/IB2012/002854 WO2013068847A2 (en) 2011-11-11 2012-11-09 Compositions and methods for treatment of cytomegalovirus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018203538A Division AU2018203538A1 (en) 2011-11-11 2018-05-18 Compositions and methods for treatment of cytomegalovirus

Publications (2)

Publication Number Publication Date
AU2012335277A1 AU2012335277A1 (en) 2014-06-12
AU2012335277B2 true AU2012335277B2 (en) 2018-06-14

Family

ID=48290708

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2012335277A Active AU2012335277B2 (en) 2011-11-11 2012-11-09 Compositions and methods for treatment of cytomegalovirus
AU2018203538A Abandoned AU2018203538A1 (en) 2011-11-11 2018-05-18 Compositions and methods for treatment of cytomegalovirus
AU2020264275A Active AU2020264275B2 (en) 2011-11-11 2020-11-03 Compositions and methods for treatment of cytomegalovirus

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018203538A Abandoned AU2018203538A1 (en) 2011-11-11 2018-05-18 Compositions and methods for treatment of cytomegalovirus
AU2020264275A Active AU2020264275B2 (en) 2011-11-11 2020-11-03 Compositions and methods for treatment of cytomegalovirus

Country Status (14)

Country Link
US (3) US9777043B2 (enExample)
EP (2) EP2776567B1 (enExample)
JP (2) JP6232544B2 (enExample)
KR (2) KR102340558B1 (enExample)
CN (3) CN104271745A (enExample)
AU (3) AU2012335277B2 (enExample)
BR (2) BR112014011229B1 (enExample)
CA (2) CA2889659C (enExample)
DK (1) DK2776567T3 (enExample)
ES (1) ES2874233T3 (enExample)
MX (2) MX353189B (enExample)
PT (1) PT2776567T (enExample)
RU (2) RU2019139064A (enExample)
WO (1) WO2013068847A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3330368B1 (en) 2009-06-18 2021-07-21 Kiyatec Inc. Bioreactor system
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
PT2776567T (pt) 2011-11-11 2021-05-25 Variation Biotechnologies Inc Composições e métodos para o tratamento de citomegalovírus
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
US10006096B2 (en) * 2012-03-27 2018-06-26 Variation Biotechnologies Inc. Methods for detection of anti-cytomegalovirus neutralizing antibodies
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
BR112015008930A2 (pt) * 2012-10-30 2017-11-21 Redvax Gmbh vacinas baseadas em partícula recombinante contra a infecção por citomegalovírus humano
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US10273285B2 (en) 2014-06-18 2019-04-30 Morphosys Ag Fusion proteins and uses thereof
KR101678740B1 (ko) * 2014-10-24 2016-11-23 단국대학교 천안캠퍼스 산학협력단 세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질
WO2016149426A1 (en) * 2015-03-16 2016-09-22 The Broad Institute, Inc. Constructs for continuous monitoring of live cells
WO2017068077A1 (en) 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019209632A1 (en) * 2018-04-24 2019-10-31 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
SG11202010821TA (en) * 2018-05-04 2020-11-27 Spybiotech Ltd Vaccine composition
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
KR20220038608A (ko) * 2019-05-31 2022-03-29 배리에이션 바이오테크놀로지스 아이엔씨. 다형성 교모세포종의 치료를 위한 면역치료 조성물
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
GB201910651D0 (en) * 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle
EP4028051A1 (en) * 2019-09-09 2022-07-20 GlaxoSmithKline Biologicals S.A. Immunotherapeutic compositions
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
IL300001A (en) 2020-07-24 2023-03-01 Massachusetts Gen Hospital Enhanced virus-like particles and methods of use thereof for delivery to cells
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN115948468A (zh) * 2022-09-09 2023-04-11 青岛大学 一种人巨细胞病毒重组载体及其制备方法和应用
WO2024243675A1 (en) * 2023-06-02 2024-12-05 Variation Biotechnologies Inc. Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123494A1 (en) * 2007-07-31 2009-05-14 William Staplin Momlv-based pseudovirion packaging cell line

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
JPS61103895A (ja) * 1984-10-26 1986-05-22 Green Cross Corp:The ＨＢｓＡｇの精製方法
WO1989007143A1 (en) * 1988-01-29 1989-08-10 Chiron Corporation Recombinant cmv neutralizing proteins
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
DE19856463B4 (de) * 1998-11-26 2006-02-02 Heinrich-Pette-Institut Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
EP1222281B1 (en) * 1999-09-30 2006-11-15 University of Washington Immunoligically significant herpes simplex virus antigens
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
PT2311848E (pt) 2002-12-23 2013-10-03 Vical Inc Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano
AU2004257214B2 (en) 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
RU2290204C1 (ru) * 2005-07-27 2006-12-27 Общество с ограниченной ответственностью "Аванген" Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
EP2044224A4 (en) 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc CHIMERIC VIRUS TYPE PARTICLES
US20110250675A1 (en) 2008-03-26 2011-10-13 Life Technologies Corporaiton Virus-Like Particle Mediated Cellular Delivery
GB0907935D0 (en) 2009-05-08 2009-06-24 Henderson Morley Plc Vaccines
PT2776567T (pt) 2011-11-11 2021-05-25 Variation Biotechnologies Inc Composições e métodos para o tratamento de citomegalovírus
US9907844B2 (en) 2013-12-11 2018-03-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123494A1 (en) * 2007-07-31 2009-05-14 William Staplin Momlv-based pseudovirion packaging cell line

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GARRONE, P. et al., Science Translational Medicine, 2011, Vol. 3, 94ra71 *

Also Published As

Publication number Publication date
AU2012335277A1 (en) 2014-06-12
JP6657150B2 (ja) 2020-03-04
CN111995664B (zh) 2024-08-02
KR102301463B1 (ko) 2021-09-14
US20230272013A1 (en) 2023-08-31
KR20190104644A (ko) 2019-09-10
US20170349634A1 (en) 2017-12-07
KR20140095556A (ko) 2014-08-01
EP2776567B1 (en) 2021-01-20
ES2874233T3 (es) 2021-11-04
CN104271745A (zh) 2015-01-07
MX2014005653A (es) 2014-09-04
AU2020264275A1 (en) 2020-11-26
CN111995664A (zh) 2020-11-27
EP2776567A2 (en) 2014-09-17
CA2889659C (en) 2023-03-14
WO2013068847A2 (en) 2013-05-16
CA2889659A1 (en) 2013-05-16
CA3166278A1 (en) 2013-05-16
US12421283B2 (en) 2025-09-23
WO2013068847A3 (en) 2014-10-30
RU2737530C1 (ru) 2020-12-03
KR102340558B1 (ko) 2021-12-21
US9777043B2 (en) 2017-10-03
MX353189B (es) 2018-01-05
JP6232544B2 (ja) 2017-11-22
EP2776567A4 (en) 2015-12-30
BR122019027913B1 (pt) 2021-11-30
MX387666B (es) 2025-03-18
AU2018203538A1 (en) 2018-06-07
US11248026B2 (en) 2022-02-15
AU2020264275B2 (en) 2023-12-14
PT2776567T (pt) 2021-05-25
CN107875382A (zh) 2018-04-06
CN107875382B (zh) 2024-03-08
RU2019139064A (ru) 2020-01-27
BR112014011229B1 (pt) 2021-10-13
JP2018023374A (ja) 2018-02-15
EP3854416A1 (en) 2021-07-28
JP2015505299A (ja) 2015-02-19
BR112014011229A2 (pt) 2017-05-09
US20140308308A1 (en) 2014-10-16
DK2776567T3 (da) 2021-04-26

Similar Documents

Publication Publication Date Title
AU2020264275B2 (en) Compositions and methods for treatment of cytomegalovirus
JP3881689B2 (ja) 免疫不全ウイルス用の遺伝子ワクチン
CN106999565B (zh) 重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗
KR101234981B1 (ko) 핵산 구조물
JP2003529559A (ja) 新規用途
JP2010187681A (ja) ＨＩＶに対する免疫のためのｇｐ１２０と、Ｎｅｆ及び／又はＴａｔを含むワクチン
JP2007259870A (ja) Ｄｎａワクチン及び組換えウイルスベクターとして作用し得る二機能性プラスミド
EA021391B1 (ru) Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор
JP2000517290A (ja) 保護的及び治療的な遺伝子免疫化のための方法及び組成物
JP2000506727A (ja) 組換え生ネコ免疫不全ウイルスおよびプロウイルスｄｎａワクチン
WO2015181142A1 (en) Cytomegalovirus complexes and uses thereof
CN110256539B (zh) O型口蹄疫病毒新型基因工程亚单位疫苗
HU211673A9 (en) Coccidiosis vaccines
JP2000502900A (ja) 組換えウイルス偽粒子ならびにそのワクチンおよび抗腫瘍性用途
JP2006511211A (ja) ネコ白血病ウィルスによるネコ感染症のようなオンコウィルス感染症に対するワクチン
JP2005519959A (ja) Ｈｉｖに対する強化された免疫応答を誘導する方法
JP2006503800A (ja) Ｈｉｖに対する強化された免疫応答を誘導する方法
WO2013126469A1 (en) Chimeric dna vaccine compositions and methods of use
JP2939488B2 (ja) ＨＢｃもしくはＨＢｅ抗原とＨＩＶ中和エピトーからなる混成抗原粒子およびその製法
WO2004056391A1 (en) A method of immunisation and agents useful for same
CN118354790A (zh) 用于表达人乳头瘤病毒(hpv)抗原的慢病毒载体及其在治疗hpv诱发癌症中的应用
US20030118601A1 (en) FIV vaccine
EP1729801A2 (en) Mutant viral nucleic acids and vaccine containing same

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ANDERSON, DAVID E. AND FLUCKIGER, ANNE-CATHERINE

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME TO VARIATION BIOTECHNOLOGIES INC.

FGA Letters patent sealed or granted (standard patent)